Navigation Links
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS). At one year, XIENCE V demonstrated a significantly lower incidence of major adverse cardiac events (MACE) compared to TAXUS (6.2% XIENCE V vs. 9.1% TAXUS, p-value= 0.023) in the trial's primary endpoint, which is a composite of all death, non-fatal heart attack (myocardial infarction) and target vessel revascularization (TVR). Additionally, XIENCE V demonstrated a significantly lower rate of stent thrombosis compared to TAXUS (0.7% XIENCE V vs. 2.6% TAXUS, p-value=0.002), a significantly lower rate of TVR (2.4% XIENCE V vs. 6.0% TAXUS, p-value=0.0001), and a significantly lower rate of TLR (1.7% XIENCE V vs. 4.8% TAXUS, p-value=0.0002).

The results from the COMPARE trial were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"The COMPARE trial, which studied a real-world, complex patient population, reaffirms what we saw in SPIRIT IV earlier today and what we've seen throughout our SPIRIT family of trials - with XIENCE V showing consistent, outstanding performance compared to TAXUS, whether it's TAXUS Express in SPIRIT IV or now TAXUS Liberte in the investigator-initiated study COMPARE," said John Capek, Ph.D., executive vice president, Medical Devices, Abbott.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping ope
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
2. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
6. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
9. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... has announced today that they have received CE ... Device. Velox CD™ provides a safe and predictable ... procedures. The single size velox CD™ is indicated ... 5F to 8F.  Velox CD™ utilizes ...
(Date:7/30/2014)... 2014  InnoPharma, Inc. today announced the first generic ... of Zyprexa® injection), in Canada.  Olanzapine is indicated for ... patients with schizophrenia or bipolar I mania. ... has entered into an agreement with Sandoz Canada Inc., ... use, sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... WIXOM, Mich., Sept. 19 Rockwell Medical,Technologies, ... innovative manufacturer and,developer of concentrates and specialty ... announced today that it has commenced,enrollment in ... Ferric,Pyrophosphate (SFP), a physiological iron-maintenance therapy drug. ...
... ALEXANDRIA, La., Sept. 18 Life Recovery ... an emerging provider of,groundbreaking medical devices for the ... System has been granted European CE,Mark (Conformite Europeene) ... e.g., to induce hypothermia in patients to,preserve cardiac ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System 2
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed ... study, published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel ...
(Date:7/30/2014)... 2014 The Ehlers-Danlos National Foundation (EDNF) ... Sandra Aiken Chack will serve as chair. The board ... 2014 Annual Learning Conference in Houston, Texas July 10-12. ... agenda ahead of us. From the rollout of the ... the Greater Baltimore Medical Center to our September physicians ...
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help consumers ... Quote tool on its website, LTCconsumer.com , announced Nathan ... free and unlimited. , The Instant Quote tool ... age, gender, and state of residence – and delivers a ... enter any contact information to get started). There is no ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... to U.S. Sens. Thad Cochran (R-MS) and Roger ... improvements in telemedicine coverage under Medicare, Medicaid and ... Wicker, both Mississippi Republicans, introduced the Telehealth Enhancement ... a House version, H.R. 3306, introduced by Rep. ...
(Date:7/30/2014)... 2014 Hospitals continually face the ... care that their practitioners provide. During a recent ... discussed the importance of establishing effective peer review ... and quality of care. , With regard ... Rowe elaborated on setting performance expectations, conducting regular ...
Breaking Medicine News(10 mins):Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
... , WOODLAND HILLS, Calif., Sept. 22 ... the California Governor,s Council on Physical Fitness and Sports, is ... moving and empower them to make healthy lifestyle choices now ... view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/livelikeachampion/40152/ ...
... , , RICHMOND, Va., Sept. 22 ... Richmond Health System has been named among the Top Ten 2009 ... benefits. Bon Secours Richmond has been named to Working Mother ,s ... Ten in both 2006 and 2009. , , "Being ...
... ... launch of two newly redesigned websites, R&D ( http://www.rdmag.com ) and Wireless Week ( ... to foster an online community for their users. , ... Rockaway, New Jersey (PRWEB) September 22, 2009 -- ...
... , DUQUESNE, Pa., Sept. 22 Wherever you ... the house. From pulling out blankets, replacing smoke detector batteries, varying ... "flipping" their home routines in the fall. , ... , If you are one of the estimated ...
... IBI Lost Productivity Calculators based on research with ... Sept. 22 To enable employers to estimate the productivity ... created three proprietary, on-line Lost Productivity Calculators for its members. ... company, a specific occupation group, or a specific group of ...
... Oncology (ESMO) has recognized the outstanding achievements of three ... the 2009 ESMO Award, Hamilton Fairley Award and ESMO ... Lead for Medical Oncology, Institute of Cancer, Barts and ... the 2009 Hamilton Fairley Award. The award commemorates one ...
Cached Medicine News:Health News:Video: Anthem Blue Cross and the California Governor's Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 2Health News:Video: Anthem Blue Cross and the California Governor's Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 3Health News:Bon Secours Richmond Named A Top Ten 2009 Working Mother 100 Best Company 2Health News:Bon Secours Richmond Named A Top Ten 2009 Working Mother 100 Best Company 3Health News:Bon Secours Richmond Named A Top Ten 2009 Working Mother 100 Best Company 4Health News:Advantage Business Media Launches Enhanced Websites 2Health News:Advantage Business Media Launches Enhanced Websites 3Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 2Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 3Health News:Integrated Benefits Institute Launches Productivity Modeling Tools to Help Employers Estimate the Impact of Absent Employees 2Health News:ESMO recognizes leading oncologists with prestigious awards 2Health News:ESMO recognizes leading oncologists with prestigious awards 3
... F340 is a basic laboratory system for ... results can be obtained when used with ... electrode. • Fast and easy one and ... for five buffers (pH 1.68, 4.00, 7.00, ...
... the multifunctional high-end microplate reader with outstanding ... modes., Fluorescence Intensity - FRET , ... HTRF, AlphaScreen , Luminescence , ... emission microplate reader with fastest read times. ...
... microplate reader combines improved flexibility ... with a wide range of ... the flexibility, sensitivity and high ... is the ideal detection solution ...
... for Ultra High Throughput Screening (UHTS), ... detection performance. Allows for smooth transfer ... development by sharing all the detection ... fluorescence intensity, fluorescence polarization, time-resolved fluorescence, ...
Medicine Products: